Trial Profile

A phase II trial assessing Resveratrol (JNS-108/JOTROL) for mild cognitive imparement (MCI)

Status: Planning

Phase of Trial: Phase II

Latest Information Update: 29 Apr 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

08 Apr 2025 According to a Jupiter Neurosciences media release, the company has applied for a $16.5 million NIH grant to support a Phase II trial in Mild Cognitive Impairment/early Alzheimer's. This grant, if obtained successfully, will be used to fund a 3-year trial beginning in late 2025. A decision for this funding is expected in May 2025.
23 Nov 2019 New trial record
18 Nov 2019 According to a Jupiter Orphan Therapeutics, IND filing is anticipated in the second half of 2020.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com